Integra Lifesciences Holdings Corp. IART

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000917520

D

fourth fifth of 367 graded peers in healthcare

rank 236 of 367; percentile 64.2; sampling error 2.5 points; lower is stronger

A B C D E


D, the sloth



Scoreboard


Profitability	C/D percentile 59.9
Solvency	C percentile 49.4
Growth and financing	C percentile 50.1
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $3.6B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	10 of 14
Graded from	filings received through Feb 26, 2026 263 days before the rescan; latest periodic filing 10-Q received Oct 23, 2026
Last close	$14.40 2026-11-13; market equity $1.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

- Government Regulation" of this Annual Report on Form 10-K. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of our medical devices. We are also subject to regulations that may apply to certain of our products that are Drug/Device Combination products or are considered to be subject to pharmaceutical regulations outside the U.S.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.9						
Gross profitability	23.1%	32.3%		59.1	365	2025-12-31
Return on invested capital	(25.2%)	9.3%		83.6	74	2025-12-31
Accruals ratio	(14.8%)	(6.6%)		30.1	799	2025-12-31
Gross margin stability, five years	4.2 pts	2.8 pts		66.8	242	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 49.4						
Twelve-month failure probability	0.11%	0.08%	54.1	245	2026-09-30	
Altman Z double-prime	1.17	(0.31)	31.8	743	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.54x	2.96x	62.4	825	2025-12-31	
Growth and financing, sleeve percentile 50.1						
Revenue growth, three-year compound	1.6%	10.1%	68.3	411	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	(2.5%)	2.3%	57.7	693	2025-12-31	
Net share issuance, one year	0.9%	2.4%	24.4	627	2026-02-25	

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
231	Beam Therapeutics Inc. (BEAM)	62.8	D	
232	AbbVie Inc. (ABBV)	63.1	D	
233	Perspective Therapeutics, Inc. (CATX)	63.4	D	dilution, short runway, fortress balance sheet
234	Iovance Biotherapeutics, Inc. (IOVA)	63.7	D	dilution, short runway
235	Royalty Pharma plc (RPRX)	63.9	D	
236	Integra Lifesciences Holdings Corp. (IART)	64.2	D	
237	AIM ImmunoTech Inc. (AIM)	64.5	D	late filer, degenerate inputs, distress
238	AbCellera Biologics Inc. (ABCL)	64.8	D	
239	Cardiff Oncology, Inc. (CRDF)	65.0	D	short runway, fortress balance sheet
240	Caribou Biosciences, Inc. (CRBU)	65.3	D	short runway
241	Arvinas, Inc. (ARVN)	65.6	D	fortress balance sheet

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	35.6%	(1.5%)	72
Distance from 52-week high	(27.5%)	(32.0%)	53
EBIT to enterprise value	(31.5%)	(1.8%)	21
Free cash flow yield	(2.8%)	(1.0%)	44
Book value to price	0.95	0.29	84
Sales to price	1.46	0.29	87

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	(8.1%)	19.1%	18
Relative strength against the sector, log excess return	0.14	(0.18)	72

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$252.3M
Operating cash flow, four quarters	$140.4M
Months of runway	not finite
Days since last periodic filing	24 (10-Q received Oct 23, 2026)
Median daily dollar volume, 63 sessions	$14.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6B	2025-12-31	2026-02-26	10-K	26-000011
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$803.6M	2025-12-31	2026-02-26	10-K	26-000011
3	assets	us-gaap:Assets	$3.6B	2025-12-31	2026-02-26	10-K	26-000011
4	operating income	us-gaap:OperatingIncomeLoss	-$493.4M	2025-12-31	2026-02-26	10-K	26-000011
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$563.5M	2025-12-31	2026-02-26	10-K	26-000011
6	income tax	us-gaap:IncomeTaxExpenseBenefit	-$47.0M	2025-12-31	2026-02-26	10-K	26-000011
7	total debt	us-gaap:LongTermDebt	$726.6M	2025-12-31	2026-02-26	10-K	26-000011
8	book equity	us-gaap:StockholdersEquity	$1.0B	2025-12-31	2026-02-26	10-K	26-000011
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$235.0M	2025-12-31	2026-02-26	10-K	26-000011
10	total debt	us-gaap:LongTermDebt	$760.5M	2024-12-31	2025-02-25	10-K	25-000017
11	book equity	us-gaap:StockholdersEquity	$1.5B	2024-12-31	2026-02-26	10-K	26-000011
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$246.4M	2024-12-31	2026-02-26	10-K	26-000011
13	net income	us-gaap:NetIncomeLoss	-$516.5M	2025-12-31	2026-02-26	10-K	26-000011
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$50.4M	2025-12-31	2026-02-26	10-K	26-000011
15	assets	us-gaap:Assets	$4.0B	2024-12-31	2026-02-26	10-K	26-000011
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6B	2024-12-31	2026-02-26	10-K	26-000011
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$728.5M	2024-12-31	2026-02-26	10-K	26-000011
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2023-12-31	2026-02-26	10-K	26-000011
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$656.8M	2023-12-31	2026-02-26	10-K	26-000011
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6B	2022-12-31	2025-02-25	10-K	25-000017
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$587.4M	2022-12-31	2025-02-25	10-K	25-000017
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2021-12-31	2024-02-28	10-K	24-000022
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$597.8M	2021-12-31	2024-02-28	10-K	24-000022
24	current assets	us-gaap:AssetsCurrent	$1.2B	2025-12-31	2026-02-26	10-K	26-000011
25	current liabilities	us-gaap:LiabilitiesCurrent	$456.0M	2025-12-31	2026-02-26	10-K	26-000011
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$423.4M	2025-12-31	2026-02-26	10-K	26-000011
27	liabilities	us-gaap:Liabilities	$2.6B	2025-12-31	2026-02-26	10-K	26-000011
28	depreciation amortization	us-gaap:Depreciation	$44.8M	2025-12-31	2026-02-26	10-K	26-000011
29	operating income	us-gaap:OperatingIncomeLoss	$111.5M	2023-12-31	2026-02-26	10-K	26-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$51.4M	2023-12-31	2024-02-28	10-K	24-000022
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$81.4M	2025-12-31	2026-02-26	10-K	26-000011
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$129.4M	2024-12-31	2026-02-26	10-K	26-000011
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$104.4M	2024-12-31	2026-02-26	10-K	26-000011
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$140.0M	2023-12-31	2026-02-26	10-K	26-000011
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$66.9M	2023-12-31	2026-02-26	10-K	26-000011
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$264.5M	2022-12-31	2025-02-25	10-K	25-000017
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$42.3M	2022-12-31	2025-02-25	10-K	25-000017
38	current assets	us-gaap:AssetsCurrent	$1.1B	2024-12-31	2026-02-26	10-K	26-000011
39	current liabilities	us-gaap:LiabilitiesCurrent	$922.1M	2024-12-31	2026-02-26	10-K	26-000011
40	assets	us-gaap:Assets	$3.8B	2023-12-31	2025-02-25	10-K	25-000017
41	assets	us-gaap:Assets	$3.9B	2022-12-31	2024-02-28	10-K	24-000022
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	77,937,208	2026-02-25	2026-02-26	10-K	26-000011
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	77,218,920	2025-02-24	2025-02-25	10-K	25-000017

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.